The evolution of therapeutic modalities drives the adoption of single-use technologies.
Avid Bioservices Adds Single-Use Bioreactors to Expand Manufacturing in California
May 1st 2017Avid, a wholly owned subsidiary of Peregrine Pharmaceuticals, will upgrade its Myford, California clinical and commercial manufacturing facility with multiple Mobius 2000-L single-use bioreactors from MilliporeSigma, the companies announced on May 1, 2017.
Sandoz’s Rituximab and Etanercept Biosimilars Recommended for European Approval
April 24th 2017Sandoz, a Novartis division, announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions recommending the approval of its biosimilars rituximab and etanercept in Europe, for the same indications as the respective reference medicines.